Tarsus Pharmaceuticals Hits New 52-Week High of $71.15

Tarsus Pharmaceuticals, Inc. has reached a significant milestone by hitting a new 52-week high of USD 71.15 on October 13, 2025. This achievement underscores the company's strong performance in the pharmaceuticals and biotechnology sector, where it has demonstrated remarkable growth over the past year, with a staggering 116.96% increase compared to the S&P 500's 13.36% performance.
With a market capitalization of USD 2,402 million, Tarsus Pharmaceuticals is classified as a small-cap company. The firm has shown positive results for the last three consecutive quarters, with net sales reaching a peak of USD 102.66 million. Despite being loss-making, the company has exhibited resilience, as indicated by its operating profit margin, which, although negative, has shown improvement.

Additionally, promoter confidence is on the rise, with a 1.07% increase in their stake, now totaling 8.23%. This trend reflects a commitment to the company's future prospects. Overall, Tarsus Pharmaceuticals continues to demonstrate strong market performance, solidifying its position in the competitive landscape of the pharmaceuticals and biotechnology industry.